About the Authors
- Qi Zhao
-
Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Pui-Fan Wong
-
Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Susanna S. T. Lee
-
Affiliation School of Life Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Shui-On Leung
-
Affiliation Institute of Biomedical Sciences, Fudan University, Shanghai, China
- Wing-Tai Cheung
-
* E-mail: wtcheung@cuhk.edu.hk (W-TC); wangjz@nifdc.org.cn (J-ZW)
Affiliation School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Jun-Zhi Wang
-
* E-mail: wtcheung@cuhk.edu.hk (W-TC); wangjz@nifdc.org.cn (J-ZW)
Affiliation National Institutes for Food and Drug Control, Beijing, China
Competing Interests
The authors would like to declare that all authors except SOL have no competing interests. SOL is one of the co-founders of SinoMed Biosciences Ltd. At the present moment, no product relating to anti-idiotype anti-CD22 is in development. Neither any direct or indirect interests, nor funding, consultancy, or employment is provided by SinoMed or other companies for commercial-related purpose and activities. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SSTL SOL WTC JZW. Performed the experiments: QZ PFW. Analyzed the data: QZ SOL JZW WTC. Contributed reagents/materials/analysis tools: SSTL SOL WTC. Wrote the paper: QZ SOL WTC.